|
|
Vaccine Detail
|
Allogeneic/Syngeneic DC-MC38/MUC1 Fusion Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Allogeneic/Syngeneic DC-MC38/MUC1 Fusion Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: DC vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Tanaka et al., 2001)
- Immunization Route: Subcutaneous, Intravenous
- Description: A fusion cell vaccine created by fusing murine MC38 adenocarcinoma cells expressing human MUC1 antigen with either allogeneic (BALB/c, H-2^d) or syngeneic (C57BL/6, H-2^b) dendritic cells using polyethylene glycol. The resulting heterokaryons express MHC class I and II molecules, costimulatory molecules (B7-1, B7-2, ICAM), and MUC1 tumor-associated antigen. Allogeneic fusion cells exhibit dual MHC haplotype expression (H-2^d/H-2^b). Vaccination reversed immunologic tolerance to MUC1 in MUC1 transgenic mice and induced potent CTL responses: syn-FC/MUC1 generated 50% lysis of MC38/MUC1 targets, 20% of MC38, and 1.46% MUC1-specific CD8+ T cells; allo-FC/MUC1 generated 32% lysis of MC38/MUC1, 25% of MC38, 0.71% MUC1-specific CD8+ T cells, with 2-3-fold higher T cell proliferation. Both vaccines provided complete protection against tumor challenge. In therapeutic studies, syn-FC/MUC1 completely eliminated pulmonary metastases (20/20 disease-free) and allo-FC/MUC1 was highly effective (17/20 disease-free), while PBS controls developed metastases (0/20). Demonstrates that allogeneic dendritic cells can be as effective as syngeneic dendritic cells for fusion vaccines, offering clinical advantages of unlimited healthy donor DC availability (Tanaka et al., 2001).
|
| Host Response |
|
|
| References |
Tanaka et al., 2001: Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D, Gong J. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clinical immunology (Orlando, Fla.). 2001; 101(2); 192-200. [PubMed: 11683578].
|
|
